


**Dr Edwin Asturias** is paediatric infectious diseases doctor with a public health background who is currently working as Associate Director for the Centre for Global Health at the University of Colorado Anschutz Medical Campus. He was boarded in paediatrics at University of Colorado Health Sciences Centre in 1995 and Paediatric Infectious Diseases at the Johns Hopkins School of Medicine in 1998. He has led for 25 years clinical trials, implementation research and policy for introduction and safety of vaccines for children in low- and middle-income countries including Hib, pneumococcus, poliovirus, dengue, influenza, and novel coronavirus. Dr. Asturias founded and has served on the Guatemalan National Committee for Immunization Practices, the Poliovirus Contention Commission, and advisory groups for the World Health Organization, including the Global Advisory Committee on Vaccine Safety. He is now the coordinator for the Advance Vaccinology Course of the University of Geneva and Foundation Merieux in France and member of the World Health Organization Expert Advisory Group for the Malaria Vaccine. In 2020, he served his native country, Guatemala as the Presidential Commissioner for the Emergency of COVID-19. He is now leading studies on evaluating the impact of influenza and COVID-19 in agricultural workers and households, new methods for diagnosis of pneumonia and measuring the impact of novel pneumococcal vaccines and elucidating transfer of RSV maternal antibodies in anticipation of upcoming RSV vaccines. He is the member of ACIP working groups on polio and dengue in the United States and an active member on immunizations for the PAHO/WHO Collaborating Centre for Family and Child Health based at the University of Colorado.



**Isabelle Bekeredjian-Ding** is Head of the Microbiology Division and acting director of the Center for Pandemic Vaccines and Therapeutics (ZEPAL) at Paul-Ehrlich-Institut (PEI). She is an Associate Professor at the University of Bonn and holds a clinical specialization in Medical Microbiology, Virology and Epidemiology of Infection, and a research track record in immunology. Prof. Bekeredjian-Ding received Medical School training at the Universities of Heidelberg, Padua (Italy) and Mt. Sinai, New York, as well as clinical training in Munich and Heidelberg. Before joining PEI, she was deputy director of the Institute of Medical Microbiology, Immunology and Parasitology in Bonn. Prof. Bekeredjian-Ding served as a Member at the EMA CHMP Vaccines Working Party and as Chair of the Scientific Committee of the IMI2 JU program, among other offices.

**Cristina Casetti** is the Deputy Director of the Division of Microbiology and Infectious Diseases (DMID) at the National Institutes of Allergy and Infectious Diseases (NIAID), a component of the US National Institutes of Health (NIH). Dr. Casetti has a Ph.D. in virology from the University of Rome, Italy. She has conducted research on poxviruses replication at the NIH, influenza virus biology at Rutgers University and HPV vaccine development at the Vaccine Discovery Department at Wyeth (now Pfizer). In 2003 she became a Program Officer at NIAID where she was responsible for the management and direction of extramural research programs on several emerging viral diseases of global health importance including influenza and dengue. In 2016, she was appointed to coordinate the Zika research response in extramural NIAID and to manage translational research in the Virology Branch. In 2017 she was appointed as Chief of the Virology Branch in DMID. In 2019 she became the Deputy Director of DMID where she shares responsibilities with the director for the overall scientific direction, administration and management of the largest extramural Division at NIAID.





**Dr. Alejandro Cravioto** is currently a professor at the Faculty of Medicine of the National Autonomous University of Mexico in Mexico City. Dr. Cravioto served as Dean of the Faculty from and as Executive Director of the International Centre for Diarrhoeal Disease Research (icddr,b) in Dhaka, Bangladesh. He has served as Chief Scientific Officer of the International Vaccine Institute (IVI) in Seoul, Republic of Korea. Dr. Cravioto received his Medical Degree with honors from the Faculty of Medicine of UNAM. He specialized in Pediatrics at the National Institute of Pediatrics in Mexico City, followed by training at the London School of Hygiene and Tropical Medicine of the University of London, where he received a Diploma in Tropical Public Health and a Ph.D. He served as the Chair of the Strategic Advisory Group of Experts (SAGE) on Immunization of the World Health Organization from 2015 to 2022, and is currently a member of the advisory group for the Gavi Vaccine Investment Strategy 2024.

**Adrien de Chaisemartin** is the Deputy Director for Gavi, Immunization Partners, and Special Initiatives at the Bill & Melinda Gates Foundation. Adrien joined the Foundation in August 2021 where he initially led the work on Covid vaccine supply during the Covid Pandemic. Previous to joining the Foundation, Adrien was serving as the Director for Strategy Funding & Performance at Gavi, where he coordinated the design of Gavi 4.0 and 5.0 strategies and led the transformation of Gavi's engagement model with partner institutions. Before joining Gavi in 2011, Adrien worked at McKinsey & Company in Johannesburg, South Africa. For 6 years he worked on public health projects, including on MNCH strategies in Ethiopia, HIV in Botswana, climate change and health in Tanzania and other economic development projects in Kenya and South Africa. Adrien holds a Master of Science from Ecole Polytechnique, France, a Master of Applied Mathematics from Harvard University, and a Master of Public Health from Johns Hopkins University.



**Arnaud Didierlaurent** was trained as an engineer in Biotechnology in France. After gaining his Master's degree at the University of Washington (Steve Ziegler's lab) in 1999, Arnaud obtained his PhD in cellular immunology from the University of Lausanne in 2003 at ISREC under the supervision of Jean-Pierre Kraehenbuhl and Jean-Claude Sirard. Arnaud continued his work on innate immunity in the lab of Jürg Tschopp before joining the Imperial college, London, where he worked as postdoctoral fellow from 2004 to 2007 on the long-term impact of viral infection on the lungs. In 2006, he was awarded a prize from the Novartis Foundation as a research fellow in Ralph Steinman's lab at the Rockefeller University in New York. Arnaud then joined the R&D department of GlaxoSmithKline in 2008 in Belgium, where he held several leading positions in vaccine research and development. Initially head of a lab investigating the mode of action of adjuvant, Arnaud became in charge of the GSK Adjuvant System portfolio and thus directly involved in the licensure of several adjuvanted vaccines. Arnaud's scientific contributions have consequently been focused on deciphering the interplay between innate immunity and pathogen/vaccine-specific adaptive response. Before joining the University, he was global medical affairs director and responsible for the launch of the GSK Zoster vaccine in Japan and European markets, which further increased his understanding of implementation of vaccine programs. With his experience in both academic and industrial settings, Arnaud has acquired a deep understanding of how vaccines are created, developed, and deployed. He joined the Center of vaccinology in March 2020 to continue his

work on translational vaccine research as Assistant Professor. He was recently appointed by WHO as chairman of the Technical Advisory Group who provides recommendations for the Emergency Use listing of COVID-19 vaccine candidates. Since February 2023, he is the director of the Center of Vaccinology at the Faculty of Medicine in Geneva and responsible of ADVAC for the University of Geneva"

**Janet Englund, MD**, is Professor of Pediatric Infectious Diseases at the University of Washington School of Medicine and Seattle Children's Hospital. She studies new viruses, viral vaccines and novel agents for the treatment and prevention of respiratory viruses including influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 (COVID-19). She has studied maternal immunization to protect mothers and infants against pertussis, influenza, and respiratory syncytial virus. Dr. Englund's research group at Seattle Children's Hospital is part of the New Vaccine Surveillance Network of the Centers for Disease Control (2010-2021), participating in respiratory and gastrointestinal viral surveillance in King County. This group assesses vaccine effectiveness in population-based studies of healthy children. She also is a leader of the Seattle Flu Study, a group of investigators who evaluate the spread of respiratory viruses within the community and helped identify the first case of community COVID-19 in the USA. Her group evaluates new methods to diagnose and characterize viral respiratory diseases, including COVID-19. Dr. Englund has been active in national and international organizations including American Academy of Pediatrics, the CDC-sponsored Advisory Committee on Immunization Practices (ACIP), the FDA Vaccines and Related Biological Products Advisory Committee (VRPAC), and the Maternal Immunization Safety Group at the World Health Organization (WHO). She is past president of the Pediatric Infectious Disease Society, past member of the WHO Influenza working group and the Board of Directors of the Infectious Disease Society of America (IDSA), and a current member of the IDSA COVID-19 Diagnosis Working Group.



**Dr Mary Hamel** is a Senior Technical Officer in the Department of Immunization, Vaccines & Biologicals, at the World Health Organization. She is the Team Lead for the Malaria Vaccines Team and leads the RTS,S Malaria Vaccine Implementation Programme, which supports pilot implementation of the first malaria vaccine in Malawi, Kenya and Ghana. She is a medical epidemiologist with over 26 years of experience in malaria and child health research and public health. She is a medical doctor, with a specialty in internal medicine, subspecialty in infectious diseases and a diploma in Tropical Medicine and Hygiene. Dr Hamel has led and supervised numerous malaria-related studies, primarily in Africa, focusing on malaria in children, pregnant women, and HIV infected persons and transmission reduction efforts. Prior to joining WHO, she was the Deputy Chief for Science and Chief of the Strategic and Applied Science Unit for the Malaria Branch, U.S. Centers for Disease Control and Prevention (CDC). She served as the Malaria Branch Chief at KEMRI/CDC Research and Public Health Collaboration, located in Kisumu, in western Kenya from 2004 – 2010, where she served on a number of Kenya National Malaria Control Working Groups. She was the Senior Technical Advisor to the President's Malaria Initiative in Washington DC from 2010 – 2014. She lives in Switzerland with her husband and two teenage children.



**Philippe Juvin** is Chief Pharmaceutical officer and Associate Vice-President Global Product Quality Management, based at Sanofi Pasteur headquarter in Lyon since March 2013. Previously, Philippe was Quality Operations Senior Director and Chief Pharmaceutical Officer at Genzyme Polyclonals Lyon since March 2008. He started his career in the nineties and held different positions in production and quality departments of pharmaceutical companies (Genzyme Polyclonals, Solvay Pharmaceuticals, Aventis-Pharma, Boehringer Ingelheim, Roussel Diamant Ciba Geigy). In his mission as Quality Director, one of his main achievements was to bring Solvay Pharmaceuticals site based in the Lyon Region to the FDA cGMP agreement for two products in May 2007, then to prepare the new Genzyme Polyclonals biotech site to international approvals. Philippe Juvin is a Doctor in Pharmacy graduated from the Lyon Pharmacy University and he holds a master degree for Qualitology and Quality management from the Lyon Claude Bernard University.

**David C. Kaslow, MD**, is director of the Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration (US FDA). Prior to joining US FDA in October of 2022, David served as PATH's Chief Scientific Officer at PATH, supporting PATH's Drug Innovation and Access Initiative and heading PATH's Center for Vaccine Innovation and Access (CVIA). His 35+ years of experience in product development and introduction include the US government (NIH), biotech (Vical), multi-national pharma (Merck Research Laboratories), and non-profit (PATH) sectors. David served in the US Public Health Service at NIAID, and has served on a number of advisory committees, including WHO Product Development of Vaccines Advisory Committee (PDVAC). David received a B.S. in biochemistry from University of California, Davis, and a M.D. from University of California, San Francisco.



**Dr. Kathleen Neuzil** is the Myron M. Levine Professor in Vaccinology, Professor of Medicine and Pediatrics, and the Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine. She is an internationally recognized research scientist and advocate in the field of vaccinology. Throughout her career, Dr. Neuzil has conducted clinical and epidemiologic studies on vaccine-preventable diseases, yielding high-profile publications that inform policy decisions and public health actions. Dr. Neuzil's work has spanned dozens of low-resource countries with multiple vaccines, including influenza, rotavirus, human papillomavirus, Japanese encephalitis, typhoid conjugate vaccines, and most recently, COVID-19 vaccines. Dr. Neuzil was central to the domestic and global response to COVID-19. As a co-PI of the NIH-funded Leadership Group for the Vaccine and Treatment Evaluation Unit network, Dr. Neuzil was part of the strategic team evaluating COVID vaccines and therapeutics in the US and was part of the study team who designed the first COVID-19 clinical vaccine trial in the US. Dr. Neuzil directs TyVAC, the Typhoid Vaccine Acceleration Consortium, with the goal to accelerate the introduction of typhoid conjugate vaccines into low-resource countries. She has more than 300 scientific publications on vaccines and infectious diseases, and is a member of the prestigious National Academy of Medicine. Dr. Neuzil's research capabilities are complemented by 20 years of involvement in domestic and international policy,

including past membership on the US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. She is a member of the World Health Organization Strategic Advisory Group of Experts on Immunization.



In September 2022, **Aurélia Nguyen** was appointed Chief Programme Strategy Officer at Gavi, the Vaccine Alliance – the first person to hold the position. In this role, Aurélia provides strategic direction on Gavi's vaccine portfolio; ensures cohesion and coordination in implementing Gavi's current strategy and planning for the next strategic period; and incorporates key learnings into Gavi policies and programmes. Previously, Aurélia served as Managing Director of the Office of the COVAX Facility, beginning in October 2020. In this role, Aurélia led the coordination of procurement and delivery of COVID-19 vaccines to 146 countries through COVAX, the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both high-income and lower-income countries. In a previous appointment, Aurélia served as Gavi's Managing Director for Vaccines & Sustainability, leading the end-to-end work of designing Gavi's vaccine programmes. She and her team were responsible for designing ways for Gavi's resources to support financially sustainable vaccine programmes and markets, and ultimately increase uptake of life-saving vaccines. Prior to joining Gavi in 2011, Aurélia held a variety of posts between 1999 and 2010 within GlaxoSmithKline, where latterly she led the development of GSK's policies on access to medicines and vaccines in lower-income countries. She has also undertaken research for the World Health Organization (WHO) on generic medicines policies. Aurélia is a certified accountant and holds a Master's degree in Health Policy, Planning & Financing from the London School of Hygiene & Tropical Medicine and the London School of Economics. Aurélia was named by TIME magazine to the 2021 TIME100 Next list honouring "the 100 individuals who are shaping the future of their fields and defining the next generation of leadership".

Trained as an immunologist at the Pasteur Institute (Paris, France), **Prof. Steve Pascolo** used mouse models to test and develop mRNA-based vaccines (direct injection of mRNA) during his post-doc in Tuebingen, Germany from 1998 till 2000. In 2000, he co-founded CureVac with Dr. Hoerr and Dr. von der Mulbe. Dr. Pascolo was Chief Scientific Officer (CSO) of the company from 2000 till 2006, developing the technology, implementing the worldwide first GMP production of mRNA and in 2003 performing the worldwide first mRNA vaccine clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he joined the oncology department of the University Hospital of Zurich, Switzerland and continued the development of immunotherapies based on RNA. In 2008, he founded Miescher Pharma to support this work. In 2017, Dr. Pascolo implemented in Zurich an academic mRNA platform <https://www.cancer.uzh.ch/en/Research/mRNA-Platform.html>. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.





**Brett W. Petersen** is a Commander in the United States Public Health Service and currently serves as the Deputy Branch Chief for CDC's Poxvirus and Rabies Branch. He began his career at CDC as an Epidemic Intelligence Service officer with the rabies team where he participated in multiple outbreak responses and field investigations involving rabies virus and other pathogens. Among other accomplishments, Dr. Petersen led the development of national recommendations for the use smallpox vaccine in an emergency as well as for laboratory workers as the lead for the Advisory Committee on Immunization Practice (ACIP) smallpox vaccine working group. He continues to participate in outbreak responses including leading a COVID19 Response Assistance Field Team in 2020, serving as the Deputy Incident Manager for CDC's response to Zika in 2016-2017, and deploying to Liberia to assist with the Ebola response in 2014. Prior to joining CDC, Dr. Petersen received his bachelors of science from the University of California, San Diego, his masters of public health from Johns Hopkins University, and his medical degree from the University of Michigan. He completed his medical training at the University of California San Diego Medical Center and is board certified in internal medicine.

**Dr Gustavo Mendes Lima Santos** is a pharmacist with a regulatory background who is currently working as Research Scientist in the Regulatory Affairs Office at International Vaccine Institute (IVI). He completed his PhD from University of Maringa in Pharmaceutical Sciences and worked more than 20 years as regulator in the Brazilian Health Regulatory Agency (Anvisa). His activities as regulator included GMP/GCP inspections and dossier reviewer of vaccines and medicines. He is the formal General Manager of Medicines and Biological Products at Anvisa, in charge of establishing Brazilian regulations during COVID-19 pandemic. He has published more than 30 research and review articles on regulatory science. He is the member of Product Development for Vaccines Advisory Committee, which is an independent standing WHO committee of experts which provides external advice to WHO related to priority infectious disease pathogens, associated vaccine and monoclonal antibody product development approaches and related manufacturing and delivery technologies.



**Melanie Saville, MB, BS**, joined the Coalition for Epidemic Preparedness Innovations (CEPI) in November 2017. She is the Executive Director of Vaccine Research & Development, and leads the technical teams supporting the vaccine development and enabling science projects funded by CEPI and is the R&D and Manufacturing workstream leader for COVAX. Melanie is a physician specialized in virology with 20 yrs of experience in the development and licensure of vaccines for the developed and developing world. Over the years, she has contributed to the development and licensure of several vaccines for seasonal and pandemic influenza, pediatric combinations, Rabies, Japanese Encephalitis and Dengue vaccine in Europe, US and the international area. She is currently a Board member of the International Vaccine Institute (IVI).

Melanie obtained her medical degree from University College, London in 1993. She also obtained a Bachelor of Science in Molecular Biology from University College, London and a master's in medical Virology from Imperial College, London. In the vaccine industry, Melanie has held positions of

increasing responsibility in research and development working for Wyeth, Sanofi Pasteur and Janssen vaccines and prevention.

**Dr Adesola Yinka-Ogunleye** is an Epidemiologist and global health professional with over 15 years' experience in national and international public health roles. Her interest is in disease surveillance and public health response to infectious diseases. At the Nigeria Centres for Disease Control, Adesola supported the Nigeria surveillance and response system, including leading the adaptation and review of the Nigeria Integrated Disease Surveillance and Response (IDSR) guidelines in 2019/2020. She worked extensively investigating and responding to epidemics and complex multi-sectoral public health events including cholera, Lassa Fever, meningitis, polio, yellow fever, and mpox. Adesola led Nigeria's response and control of cholera between 2016 and 2018 and the response to mpox resurgence between 2017 and 2020. Adesola is well experienced in implementation of vaccination



as a public health intervention during infectious diseases outbreaks. She is a member of the WHO SAGE working group on Smallpox/monkeypox vaccine as well as mpox Clinical Management and Infection Prevention and Control working groups. She was a member of the Nigeria Polio Emergency Operations Centre. She holds BDS and MPH (Field Epidemiology) degrees from the University of Ibadan, Nigeria and, in-view, a PhD in Infectious Diseases Epidemiology at the Institute of Global Health, University College London, UK. She is a 2018/19 African Public Health Leaders Fellow, Chatham House, UK. She is well published.